Q-omics provides the consensus-scored SPATA12 profile across patient tissues and cancer cell-line models. SPATA12 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SPATA12 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, SPATA12 RNA expression shows 13,440 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRP, and COAD as cancer lineages where SPATA12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATA12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATA12 survival associations across molecular data types. SPATA12 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATA12 RNA expression–survival associations across cancer types. High SPATA12 expression shows unfavorable associations in LGG, but favorable associations in KIRP, HNSC, READ, COAD and DLBC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for SPATA12 RNA expression.
This table summarizes SPATA12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SPATA12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPATA12 shows higher tumor expression in COAD, KIRP, THCA, BRCA, KIRC and CHOL. The COAD box plot shows higher SPATA12 RNA expression in tumor versus normal tissue (log2 FC = +1.162, t-test p < 0.001).
This table shows molecular features associated with SPATA12 in patient tissues and cancer cell lines. In patient samples, SPATA12 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, SPATA12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and SKIN.
